Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
(tested or 100% immunogen sequence identity)
Monkey (at least 90% immunogen sequence identity)
Western blot (1:100)
PCSK9 antibody was raised against synthetic peptide corresponding to aa490-502 [SRSGKRRGERMEA] of human PCSK9. Species sequence Homology. Percent identity by BLAST analysis: Human, Chimpanzee, Orangutan, Gibbon (100%); Gorilla, Macaque, Monkey, Titi monkey, Woolly monkey, Colobus monkey, Tamarin (92%); Marmoset, Spider monkey, Elephant, Opossum (85%).
Recognizes human PCSK9. Detects mainly the mature form of the protein ranging from 62-66kD in tissues and cells such as liver, kidney and colon cancer cells. Species cross-reactivity: Mouse and rat. Species sequence Homology: Mouse: ~69% (9/13aa [SRSGrRRGdwiEA]); Rat: ~77% (10/13aa [SRSGrRRGdRiEA]).
Suitable for use in Western Blot, Immunocytochemistry and Immunofluorescence. Western Blot: 1:100 (3 ug/ml). Immunofluorescence (IC): 1:25 (16 ug/ml).
TBS, pH 7.4, 0.1% BSA, 0.02% sodium azide.
Short term: 4°C. Long term: Store at -20°C. Avoid freeze-thaw cycles.
Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway.